Medical management of pancreatic neuroendocrine tumors

被引:33
作者
Delaunoit, Thierry [2 ,3 ]
Neczyporenko, Florence [2 ,4 ]
Rubin, Joseph [1 ]
Erlichman, Charles [1 ]
Hobday, Timothy J. [1 ]
机构
[1] Mayo Clin, Dept Oncol, Coll Med, Rochester, MN 55905 USA
[2] Mayo Clin, Program Mol Med, Coll Med, Rochester, MN 55905 USA
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] CHU St Pierre, Brussels, Belgium
关键词
D O I
10.1111/j.1572-0241.2007.01643.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Pancreatic neuroendocrine tumors (PNET) are rare malignancies frequently diagnosed at a late stage, with symptoms related to bulky disease. Hormonal secretion, when responsible for symptoms, permits, on the other hand, early diagnosis of the disease. Surgery remains the cornerstone of therapeutic management. However, due to advanced disease, many patients are not candidates for aggressive surgical therapy. Tumor growth control and symptom management are thus achieved through medical approaches, including somatostatin (SST) analogs, chemotherapy, interferon, and more recently, targeted therapy. The purpose of this review is to collect, examine, and analyze data available in the literature regarding contemporary therapeutic management of PNET, with emphasis on medical approaches. It also offers perspectives on the future of molecular targeted therapies in these neoplasms. However, we point out that much of the literature published to date includes noncomparative studies (mainly phase 11 studies), leading to thorny interpretation of the results. METHODS: A systematic search of all the literature in English regarding PNET was performed, based on a MEDLINE search (Pubmed) carried out from January 1970 to May 2005. RESULTS: Approximately 40 trials, including over 1,000 patients, have been retrieved from our MEDLINE search. SST analogs and interferon therapies do allow control over hormone secretion and subsequent symptoms in the majority of treated subjects, but offer a poor tumor growth control rate. Chemotherapies, although more efficient in reducing tumor burden, are often toxic. New approaches such as immunotherapy and targeted therapies are still under investigation. CONCLUSIONS: Whether alone or in combination with surgery, conventional medical therapies represent a crucial aspect of PNET management. Hopefully, in the near future, a new era of antitumoral agents, such as targeted therapies, will strengthen our therapeutic arsenal, either alone or combined with other therapies.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 74 条
[1]   ISLET CELL TUMORS METASTATIC TO THE LIVER - EFFECTIVE PALLIATION BY SEQUENTIAL HEPATIC-ARTERY EMBOLIZATION [J].
AJANI, JA ;
CARRASCO, CH ;
CHARNSANGAVEJ, C ;
SAMAAN, NA ;
LEVIN, B ;
WALLACE, S .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (03) :340-344
[2]   Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours [J].
Aparicio, T ;
Ducreux, M ;
Baudin, E ;
Sabourin, JC ;
De Baere, T ;
Mitry, E ;
Schlumberger, M ;
Rougier, P .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (08) :1014-1019
[3]   Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours [J].
Bajetta, E ;
Ferrari, L ;
Procopio, G ;
Catena, L ;
Ferrario, E ;
Martinetti, A ;
Di Bartolomeo, M ;
Buzzoni, R ;
Celio, L ;
Vitali, M ;
Beretta, E ;
Seregni, E ;
Bombardieri, E .
ANNALS OF ONCOLOGY, 2002, 13 (04) :614-621
[4]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[5]   PANCREATIC-ISLET CELL-CARCINOMA .2. RESULTS OF THERAPY WITH STREPTOZOTOCIN IN 52 PATIENTS [J].
BRODER, LE ;
CARTER, SK .
ANNALS OF INTERNAL MEDICINE, 1973, 79 (01) :108-118
[6]   INHIBITION OF CELL-PROLIFERATION BY THE SOMATOSTATIN ANALOG RC-160 IS MEDIATED BY SOMATOSTATIN RECEPTOR SUBTYPES SSTR2 AND SSTR5 THROUGH DIFFERENT MECHANISMS [J].
BUSCAIL, L ;
ESTEVE, JP ;
SAINTLAURENT, N ;
BERTRAND, V ;
REISINE, T ;
OCARROLL, AM ;
BELL, GI ;
SCHALLY, AV ;
VAYSSE, N ;
SUSINI, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1580-1584
[7]   STIMULATION OF TYROSINE PHOSPHATASE AND INHIBITION OF CELL-PROLIFERATION BY SOMATOSTATIN ANALOGS - MEDIATION BY HUMAN SOMATOSTATIN RECEPTOR SUBTYPES SSTR1 AND SSTR2 [J].
BUSCAIL, L ;
DELESQUE, N ;
ESTEVE, JP ;
SAINTLAURENT, N ;
PRATS, H ;
CLERC, P ;
ROBBERECHT, P ;
BELL, GI ;
LIEBOW, C ;
SCHALLY, AV ;
VAYSSE, N ;
SUSINI, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2315-2319
[8]  
CARTY SE, 1992, SURGERY, V112, P1024
[9]  
CHING JLC, 1984, DIGEST DIS SCI, V29, pS17
[10]   High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects [J].
Eriksson, B ;
Renstrup, J ;
Imam, H ;
Oberg, K .
ANNALS OF ONCOLOGY, 1997, 8 (10) :1041-1044